Our Solutions   by Brands   Tucaliv   Tocira 400 mg Injection

Tocira 400 mg Injection

Tocira 400Mg Injection

*To be consumed as directed by physician.

Therapies:

COVID 19 Management

Composition:

Each vial contains 400 mg of Tocilizumab in 20 ml (20 mg/ml)

About Tocira 400Mg Injection

Tocira 400 Infusion is a 20 ml intravenous infusion containing Tocilizumab 400 mg, a monoclonal antibody and interleukin-6 (IL-6) receptor inhibitor used to treat several chronic inflammatory and autoimmune conditions. By blocking the action of IL-6, a key inflammatory cytokine, Tocilizumab helps reduce inflammation, pain, swelling, and immune-mediated tissue damage. It is commonly prescribed for Rheumatoid Arthritis (RA) and other inflammatory disorders in patients who have not responded adequately to conventional therapies. Treatment should always be administered under the supervision of a qualified healthcare professional.

Tocira 400Mg Injection

*To be consumed as directed by physician.


Usage Instructions

  • Tocira 400 Infusion should only be administered by a healthcare professional in a hospital or clinical setting.
  • The dosage, infusion schedule, and treatment duration are determined by your doctor based on your medical condition, body weight, and response to therapy.
  • Do not miss scheduled appointments or discontinue treatment without consulting your physician.
  • During therapy, regular monitoring of blood counts, liver function, cholesterol levels, and signs of infection is recommended to ensure safe and effective treatment.

    • Benefits and Use

  • Tocira 400 Infusion is indicated for the treatment of Rheumatoid Arthritis, where it helps reduce joint pain, swelling, stiffness, and inflammation, improves physical function, and slows joint damage.
  • It may also be prescribed for selected inflammatory conditions such as Ulcerative Colitis, Crohn's Disease, Psoriasis, and Ankylosing Spondylitis, when deemed appropriate by the treating specialist.
  • By inhibiting IL-6-mediated inflammation, it helps improve symptoms, reduce disease activity, prevent flare-ups, and enhance overall quality of life.

    • Safety Information

  • Pregnancy:
  • Use during pregnancy only if clearly recommended by your doctor after carefully assessing the potential benefits and risks.
  • Breastfeeding:
  • Consult your doctor before breastfeeding, as information regarding its safety during lactation is limited.
  • Infection Risk:
  • Tocilizumab suppresses the immune system and may increase the risk of serious bacterial, viral, fungal, or opportunistic infections. Inform your doctor immediately if you develop fever, persistent cough, sore throat, diarrhea, rash, or flu-like symptoms.
  • Tuberculosis & Hepatitis Screening:
  • Patients may require screening for tuberculosis (TB) and viral hepatitis before starting treatment.
  • Liver Disorders:
  • Use with caution in patients with liver disease. Regular monitoring of liver enzymes is recommended, and the medicine is generally not advised in patients with active liver disease.
  • Kidney Disorders:
  • Use cautiously in severe kidney disease. Dose adjustment may be required based on clinical assessment.
  • Blood Monitoring:
  • Regular blood tests are recommended to monitor complete blood counts, liver function, and cholesterol levels, as treatment may affect these parameters.
  • Vaccinations:
  • Live vaccines should generally be avoided during treatment unless advised by your doctor.
  • Driving:
  • If you experience dizziness or impaired concentration after the infusion, avoid driving or operating machinery.
  • Common Side Effects:
  • Headache, high blood pressure, upper respiratory tract infections, injection/infusion site reactions, increased liver enzymes, and nasopharyngitis. Seek immediate medical attention if you develop severe allergic reactions, chest pain, difficulty breathing, persistent abdominal pain, or signs of serious infection.

    • Ingredients

    Tocilizumab 400 mg / 20 ml

    How to Use

  • Tocira 400 Infusion is administered as an intravenous (IV) infusion by a doctor or trained healthcare professional.
  • It should not be self-administered.
  • Follow your doctor's treatment schedule carefully and attend all follow-up appointments for clinical evaluation and laboratory monitoring.

    • Storage Information

  • Store refrigerated at 2°C to 8°C.
  • Do not freeze or shake.
  • Keep the vial in its original carton to protect it from light until use.

    • Dosage

    Concentrate for solution for infusion (sterile concentrate). Clear to opalescent, colourless to pale yellow solution.

    The recommended dosage for emergency use of Tocilizumab authorized under this EUA given as a single 60-minute intravenous infusion is:

    Recommended Intravenous Dosage for COVID-19
    Patients at or above 30 kg weight 8 mg/kg

    If clinical signs or symptoms worsen or do not improve after the first dose, one additional infusion of Tocilizumab may be administered at least 8 hours after the initial infusion.
    Maximum Dosage in COVID-19 patients is 800 mg per infusion.
    Tocilizumab subcutaneous administration is not authorized for the treatment of COVID-19 patients.